Cadrenal Therapeutics, Inc. CVKD
1.13 USD +0.09 (+8.65%)
At closeNov 3, 2026, 4:26 PM EST
1.13 0.00 0.00%
After hours · Nov 3, 4:26 PM ET
1.05 Day range 1.14
0.816 52-week range 13.37
- YTD
- -83.33%
- 1 year
- -91.62%
- Market cap
- 3.50M
- EPS (ttm)
- -5.33
- Shares out
- 1.66M
- Forward P/E
- -3.02
- YTD return
- -83.33%
- 1-year return
- -91.62%
- Volume
- 55.29K
- Avg volume
- 473.07K
- Open
- 1.05
- Previous close
- 1.04
- Day's range
- 1.05 – 1.14
- 52-week range
- 0.816 – 13.37
- Price target
- 35.67 (+3056.3%)
- Earnings date
- Aug 7, 2024
2Y -13.21 (-92.51%)
Key statistics
- Enterprise value
- 13.49M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 4.61
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -3.67M
- Total cash
- 4.36M
- Total debt
- 2.23K
- Return on equity
- -125.15%
- Short % of float
- 6.80%
- 50-day average
- 14.77
- 200-day average
- 9.61
Analyst view
Price target (mean) 35.67 +3056.3% upside
Now 1.13
- Target (low)
- 30.00
- Target (mean)
- 35.67
- Target (high)
- 45.00
Ratings (0m) 2 2 buy · 0 hold · 0 sell
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 7, 2024
Expected Aug 7, 2024. Consensus EPS estimate -1.87.
Financials — quick view
CVKD Revenue — quarterly 0
CVKD Net income — quarterly -3.32M
CVKD EPS — quarterly -1.14
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -1.83 | -2.18 | -0.35 | -19.13% |
| Aug 7, 2024 | Jun 1, 2024 | -19.04 | -2.25 | +16.79 | +88.18% |
| Aug 7, 2024 | Jun 1, 2024 | -19.04 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -1.05 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -1.05 | -1.50 | -0.45 | -42.86% |
| Mar 11, 2024 | Dec 1, 2023 | -1.35 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 11, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Jun 6, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 9, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Dec 18, 2023 | Noble Capital Markets | init | — | Outperform |
| Nov 20, 2023 | HC Wainwright & Co. | init | — | Buy |
About Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- cadrenal.com
News
12 Health Care Stocks Moving In Tuesday's Intraday Session 
Cadrenal Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process to Maximize Value of its Orphan Thrombo-Inflammatory Therapeutics 
Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor Conference 
Cadrenal Therapeutics to Participate in H.C. Wainwright's 28th Annual Global Investment Conference - 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's Intraday Session 
12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
Why Pyxis Tankers Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket - 12 Health Care Stocks Moving In Monday's Intraday Session
Your note
Sign in to keep a note on CVKD — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| MURPHY JOHN RAYMOND | Director | Purchase | Oct 4, 2023 | 614,792 |
| PHAM QUANG X | Chief Executive Officer | Stock Gift | Apr 9, 2024 | 6,275,000 |
| SZOT MATTHEW K | Chief Financial Officer | Stock Award(Grant) | Jan 23, 2023 | 500,000 |
| WILSON GLYNN | Director | Conversion of Exercise of derivative security | Jan 23, 2023 | 50,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Royal Bank of Canada | 0.00% | 25 | 356 | Sep 29, 2024 |
| Bank of America Corporation | 0.00% | 5 | 71 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.19% | 3,216 | 45.86K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.07% | 1,109 | 15.81K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.06% | 923 | 13.16K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.00% | 60 | 855 | Sep 29, 2024 |